Show results for
Refine by
Ischemic Injury Articles & Analysis
8 news found
The disease that Villix first targeted is ischemic reperfusion injury that occurs in organ transplant myocardial infarction, coronary artery bypass surgery, and stroke. ...
DuraGraft® protects vascular grafts against ischemic injury during bypass surgeries by reducing the incidence of complications associated with vein graft failure, leading to improved clinical outcomes. ...
Peak levels of hs troponin-I were also substantially reduced in patients receiving DuraGraft, with the greatest difference noted at 12-24 hours post CABG surgery. Troponin-I is a marker of ischemic myocardial damage and significantly lower troponin levels suggest that perfusion of the distal vascular beds and downstream myocardium following flushing with DuraGraft confers ...
Interest in bilirubin is high worldwide. This is because bilirubin has already received attention as a substance that has strong antioxidant effects and immunomodulatory effects through 30,000 papers from several decades ago. However, there were clear limitations in developing it as a new drug. This is because it is extremely hydrophobic, insoluble in water. It is Bilix that solved this problem. ...
Currently, the primary challenge ahead is the development of treatments for ischemic reperfusion injury (IRI). To date, there are no drugs approved for the treatment of IRI. ...
India represents the latest market approval for DuraGraft, a CE-marked product that protects vascular grafts against ischemic injury and is the only product approved for graft protection and preservation during bypass and other vascular surgeries. ...
The disease that Bilix has targeted is ischemic reperfusion injury caused by organ transplantation, myocardial infarction, coronary artery bypass grafting, and stroke. ...
” Because the drug Simvastatin has been demonstrated to be a neurorestorative and neuroprotective agent in ischemic brain injury, the research team hypothesized that the combination of therapeutic doses of Simvastatin and HUCBCs would increase the expression of Angiopoietin-1(Ang-1, a protein with important roles in vascular development and blood vessel ...